我院非瓣膜性房颤患者抗凝治疗现状调查分析
x

请在关注微信后,向客服人员索取文件

篇名: 我院非瓣膜性房颤患者抗凝治疗现状调查分析
TITLE:
摘要: 目的:了解非瓣膜性心房颤动患者抗凝治疗现状,为其规范化抗凝治疗提供参考。方法:选取我院2015年7月-2016年6月非瓣膜性心房颤动患者1 056例,按照《2012年欧洲心脏病学会(ESC)心房颤动治疗指南》,对患者进行血栓栓塞危险和出血风险评估,并评价其抗凝治疗规范化情况。结果:血栓栓塞危险评分≥1的例数为1 028例,占总非瓣膜性心房颤动患者的97.3%。763例患者接受抗血栓治疗,而服用华法林抗凝治疗的仅有139例。服用华法林患者出院前凝血酶原时间的国际标准化比值达标率仅30.9%。结论:非瓣膜性心房颤动患者抗凝治疗现状不容乐观,应采取有效的干预措施,提高心房颤动患者抗凝治疗规范化程度。
ABSTRACT: OBJECTIVE: To investigate the current situation of anticoagulant therapy for patients with non-valvular atrial fibrillation, and to provide reference for standardized anticoagulant therapy. METHODS: A total of 1 056 patients with non-valvular atrial fibrillation were collected from our hospital during Jul. 2015-Jun. 2016. According to 2012 European Society of Cardiology Guidelines for the Management of Atrial Fibrillation, the risks of thrombosis and hemorrhage were evaluated, and the standardized anticoagulant therapy was also evaluated. RESULTS: Among 1 056 patients with non-valvular atrial fibrillation, the number of patients with thrombosis risk score ≥1 was 1 028, accounting for 97.3%. 763 patients received antithrombosis therapy, and only 139 patients were given warfarin anticoagulant therapy. The international normalized ratio (INR) of prothrombin time in just 30.9% of patients receiving warfarin was in line with the standard before discharge. CONCLUSIONS: The anticoagulant therapy for patients with non-valvular atrial fibrillation is still not optimistic, and effective measure should be adopted to improve the standardization of anticoagulant therapy in the patients with atrial fibrillation.
期刊: 2017年第28卷第11期
作者: 王长江,费爱丽,朱航,王小琴,涂厉标
AUTHORS: WANG Changjiang,FEI Aili,ZHU Hang,WANG Xiaoqin,TU Libiao
关键字: 非瓣膜性心房颤动;华法林;抗凝;调查
KEYWORDS: Non-valvular atrial fibrillation; Warfarin; Anticoagulant; Investigation
阅读数: 123 次
本月下载数: 8 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!